CompletedNCT03643484

IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AstraZeneca
Principal Investigator
Toshimitsu Tokimoto
AstraZeneca KK
Enrollment
634 target
Eligibility
All sexes
Timeline
20182021

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03643484 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease

← Back to all trials